• Corpus ID: 76583789

Biologic agents in the management of inflammatory bowel disease: is it worth it?

  title={Biologic agents in the management of inflammatory bowel disease: is it worth it?},
  author={Tommy Choy and John McLaren Howard},
Crohn’s disease can affect any part of the GI tract, and the entire thickness of the intestinal wall is generally involved. Ulcerative colitis, on the other hand, is limited to the rectum and colon and the exterior layers of the intestinal wall are generally not affected. IBD is a lifelong disease that has a substantial impact on the quality of life of patients and has a tremendous impact on a patient’s wellbeing. There are currently no cures available for IBD and treatment is aimed towards… 

Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre

The main cost is due to biological drugs, but patients enrolled were the most severe in comparison to the whole IBD population under conventional therapy, as no cost differences were found between biologic drugs and the way of administration.



Surgery for adult Crohn's disease: what is the actual risk?

The aim of this article is to review the risk of surgery before and in the era of biologics and to discuss the impact of medications on this risk, with a focus on adult luminal CD.

Guidelines for the management of inflammatory bowel disease in adults

The present document is intended primarily for the use of clinicians in the United Kingdom, and serves to replace the previous BSG guidelines in IBD, while complementing recent consensus statements published by the European Crohn's and Colitis Organisation (ECCO).

Cost Effectiveness of Treatments for Inflammatory Bowel Disease

The purpose of this article is to review the available literature on this topic and to identify areas for future research, which highlights the challenges and limitations of existing modelling techniques.

Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease

The purpose of this review is to deal with the optimal use and cost-effectiveness of the two main monoclonal anti-TNF-α agents currently used in the management of IBD patients, i.e. the chimeric human/murine antibody infliximab and the fully human antibody adalimumab.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Based on 11 trials, there was evidence from both induction and maintenance trials that both adalimumab and infliximab therapy were beneficial compared with placebo (standard care) for adults with moderate-to-severe active CD and, for inflIXimab, for Adults with fistulising CD.

Infliximab for the treatment of acute exacerbations of ulcerative colitis.

The manufacturer's submission concluded that infliximab provides clinical benefit to patients with acute severe, steroid-refractory ulcerative colitis and is well tolerated; it also provides additional clinical benefits over ciclosporin, particularly avoidance of colectomy.

The pharmacoeconomics of biologic therapy for IBD

  • R. Cohen
  • Medicine
    Nature Reviews Gastroenterology &Hepatology
  • 2010
The past decade has been marked by the introduction and expanding use of biologic therapies for the induction and maintenance of response in patients with IBD; however, these agents have also stirred controversy over the potential economic impact that they will have upon the world's health-care systems.

Inflammatory bowel disease‐attributable costs and cost‐effective strategies in the United States: A review

This investigation offers a systematic review of the economics of IBD and evidence‐based strategies for cost‐effective management and suggests clinical practices that optimize cost‐efficiency.

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.

Patients with moderate-to-severe CD treated with adalimumab had lower 1-year risks of hospitalization and surgery than placebo patients, and both 3- and 12-month hospitalization risks were significantly lower for patients who received ad alimumab.

Biologic Therapy for Inflammatory Bowel Disease

  • B. Sands
  • Biology, Medicine
    Inflammatory bowel diseases
  • 1997
This review surveys the rationale and use of biologic therapies in inflammatory bowel disease and reports on monoclonal antibodies against CD4 and tumor necrosis factor, and interleukins 10 and 11.